JAKARTA – Advances in health technology connected to COVID-19 continue to progress. Recently, a single-dose COVID-19 vaccine made by CanSino SPH Biologics Inc was launched in Shanghai, China.
"The single-dose vaccine, named Convidecia, is one of seven COVID-19 vaccines that have received approval from the Chinese authorities," said Zhu Tao from CanSino as quoted by Antara, Sunday, January 30.
As of February 2021 Convidecia has received conditional marketing approval. Then health authorities in China feel confident that the vaccine can be used to help speed up vaccinations needed by people who are very busy or have limited mobility.
CanSino together with Shanghai Pharmaceuticals Holding Co. and Shanghai Biomedical Industry Equity Investment Fund signed a joint agreement to establish CanSino SPH to manufacture the Convidecia vaccine.
CanSino SPH built a factory in Shanghai which stands on an area of 50,000 square meters. The factory is designed to be able to produce 200 thousand doses per year.
"Less than 10 months since the agreement was signed, we can produce vaccines," said Gao Yiyi, head of Shanghai's Baoshan District, where the factory is located.
In March 2021, CanSino announced that the results of its third phase of global trial showed an efficacy rate of 63.7 percent within 14 days of injection.
The English, Chinese, Japanese, Arabic, and French versions are automatically generated by the AI. So there may still be inaccuracies in translating, please always see Indonesian as our main language. (system supported by DigitalSiber.id)
